The CeQur Simplicity patch is now FDA-cleared for up to 4 days
of wear. Each patch replaces up to 12 injections further
simplifying mealtime insulin management.
HORW, Switzerland, June 18,
2024 /PRNewswire-PRWeb/ -- CeQur®, a medical device
company dedicated to simplifying insulin delivery for individuals
on multiple daily injections, announces the FDA's recent 510(k)
clearance of CeQur Simplicity for an extended wear duration from 3
to 4 days. This update marks an advancement in mealtime insulin
management to the longest wearable insulin delivery patch,
providing people with diabetes discretion, additional convenience,
and injection-free dosing.
"We are excited to share that there are now
~5000 people with diabetes using CeQur Simplicity for their
mealtime insulin delivery," said Bradley
Paddock, President and CEO at CeQur. "With the 4-day
clearance, we hope to make it even easier for people with diabetes
to take their mealtime insulin."
A pivotal analysis of over 26,000 people with Type 2 Diabetes
(T2D) on Multiple Daily Injections (MDI) from the IQVIA database
indicated that only 21.3% achieved the ADA-recommended A1C goal of
less than 7%.(1) This study represents a large portion of insulin
users and >90% of people with T2D on multiple daily injections
who are still using pens or syringes. This data also underscores
the need for more effective insulin delivery solutions like CeQur
Simplicity, which now, with its extended 4-day wear time, aims to
improve dosing adherence and simplify diabetes management even
further.
The new 4-day clearance for CeQur Simplicity represents a
significant improvement, increasing the device's wear time by 33%
and reducing the number of applications. Each patch now replaces
over 12 mealtime injections, equating to over 1000 less injections
annually, offering a substantial benefit for individuals managing
diabetes.
This extended wear time underscores CeQur's commitment to
improving the lives of those managing diabetes, offering more
freedom and flexibility. CeQur Simplicity, with the promise of
"Mealtime Insulin, Simplified," provides a discreet and easy-to-use
solution for those seeking an alternative to traditional mealtime
insulin injections. With this clearance, CeQur Simplicity sets
itself apart as a unique, bolus-only insulin therapy, promoting
better adherence and an enhanced quality of life. Recent real-world
studies have demonstrated 94% patient satisfaction and an average
A1C reduction of 1.29%.(2,3)
"We are excited to share that there are now ~5000 people with
diabetes using CeQur Simplicity for their mealtime insulin
delivery," said Bradley Paddock,
President and CEO at CeQur. "With the 4-day clearance, we hope to
make it even easier for people with diabetes to take their mealtime
insulin."
This extension is built on the success of the initial launch and
the positive reception from users who have experienced the benefits
of the 3-day wear patch. In response to growing demand, CeQur has
successfully increased its manufacturing capacity with a fully
automated manufacturing line to support 100,000 patients and is
increasing the size of its sales force, ensuring wider
accessibility and support for the diabetes community.
"Our Market Access team has been working diligently, and as a
result of their activities, nearly 70% of commercial lives are on
formulary coverage and more are being added regularly,"
Chris Arapoff, VP of Health
Economics & Reimbursement, reported. The average patient's
copay is now less than $40/month.
CeQur will showcase the 4-day wear CeQur Simplicity insulin
patch at the American Diabetes Association's 84th Scientific
Sessions in Orlando. Attendees are
invited to Booth #1223 for demonstrations and to learn more about
the impact of this innovative diabetes management solution.
About CeQur Simplicity™
CeQur Simplicity is a simple, 4-day wearable Insulin Delivery
Device for discreet, convenient and injection-free bolus dosing.
One CeQur Simplicity patch holds up to 200 units of rapid-acting
insulin administered in two-unit increments and replaces, on
average, twelve daily mealtime injections over four days. Clinical
research has shown that nearly 90% of patients using CeQur
Simplicity reported following their insulin regimen better as
compared to multiple daily injections.(4) The patch is clinically
proven to improve glycemic control, with patients achieving
significantly improved A1C and time-in-range (TIR) goals.(5,6)
About CeQur®
CeQur is commercializing advanced, simple-to-use
insulin-delivery devices that make it easier for people living with
diabetes to adhere to therapy and stay in control of their disease.
The Company's simple, wearable devices provide freedom from
multiple daily insulin injections.
More information can be found at www.cequr.com.
References:
1. Shah, V. et al, 2024. Obesity and Disparity in Glycemic
Outcomes are Prevalent Among Adults with Type 2 Diabetes (T2D) on
Multiple Daily Injections (MDI) of Insulin: A Large US
Retrospective Cohort Study. Poster presented at ATTD 2024 poster
#532. March 6-9. Florence, Italy
2. Isaacs, D., Kruger, D., Shoger, E., Chawla, H., Patient
Perceptions of Satisfaction and Quality of Life Regarding Use of a
Novel Insulin Delivery Device, Clinical Diabetes ,
2023;41(2):198–207
3. Data on File at CeQur
4. Zraick V, Dreon D, Nalk R, Shearer D, Crawford S, Bradford J,
Levy B. 2016. Patient User Experience Evaluation of Bolus Patch
Insulin Delivery System. Poster presented at the American Diabetes
Association's 76th Scientific Sessions. Abstract 995-P.
New Orleans, LA, USA
5. Bergenstal R, Peyrot M, Dreon D, Aroda V, Bailey T, Brazg R,
Frias J, Johnson M, Klonoff D, Kruger D, Ramtoola S, Rosenstock J,
Serusclat P, Weinstock R, Naik R, Shearer D, Zraick V, Levy B.
2019. Implementation of Basal–Bolus Therapy in Type 2 Diabetes: A
Randomized Controlled Trial Comparing Bolus Insulin Delivery Using
an Insulin Patch with an Insulin Pen. Diabetes Technology and
Therapeutics 21 (5):1-13.
6. Bergenstal R., et al Comparing Patch vs Pen Bolus Insulin
Delivery in Type 2 Diabetes Using Continuous Glucose Monitoring
Metrics and Profiles; Journal of Diabetes Science and Technology
1–7, 2021
Media Contact
CeQur Media, CeQur, 1 (864) 754-0852, media@cequr.com ,
https://myceqursimplicity.com
View original content to download
multimedia:https://www.prweb.com/releases/cequr-simplicity-a-wearable-mealtime-insulin-delivery-device-obtains-fda-clearance-for-4-days-of-wear-to-further-simplify-diabetes-management-302173938.html
SOURCE CeQur